Reuters logo
5 个月前
BRIEF-Proteostasis Therapeutics reports Q4 loss per share $0.38
2017年3月30日 / 晚上8点42分 / 5 个月前

BRIEF-Proteostasis Therapeutics reports Q4 loss per share $0.38

March 30 (Reuters) - Proteostasis Therapeutics Inc

* Proteostasis Therapeutics reports fourth quarter and year-end 2016 financial results and provides corporate update

* Qtrly net loss per share attributable to common stockholders-basic and diluted $0.38

* Proteostasis Therapeutics Inc says plans for phase 1 trial, which will also investigate PTI-801 in cf patients, to run in U.S. and European sites

* Proteostasis Therapeutics Inc says expects data from patients stable on Orkambi who have been dosed with PTI-801 for 14 days in second half of 2017

* Proteostasis - Expects cash, cash equivalents, short-term investments sufficient to fund operating expenses and capex requirements through Q2 of 2018

* Proteostasis Therapeutics Inc - Qtrly loss per share $0.38

* Q4 earnings per share view $-0.52 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below